The role of pharmacists in increasing patient access to ‘compassionate use’ programmes – The Pharmaceutical Journal-PhaMed
During the COVID-19 pandemic, as healthcare systems sought ways to better prevent, treat and manage a previously unseen infection, rapid access to promising novel investigational therapies based on emerging scientific evidence from clinical trials was crucial. This ‘early’ access pathway was via ‘compassionate use’ (CU) programmes, which are something I’ve been passionate about for many years.